Nasdaq2d
Alvotech Expands Biosimilar Development Capabilities with Acquisition of Xbrane Biopharma R&D Operations
Alvotech, a biotech firm focused on biosimilar ... looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example ...
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
Amneal Pharmaceuticals, Inc. offers strong growth prospects with undervalued stock, rising revenues, reduced debt, and key ...
Morningstar2d
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
"Alvotech has a best-in-class biosimilars ... looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech ...
Morningstar4d
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding competitive ...
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript
Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ETCompany ParticipantsBreno Toledo Pires de Oliveira - Chief ...
pharmaphorum6d
Novartis decides Sandoz' future – and it's a spin-out
The Swiss pharma group said this morning that the separation "is in the best interest of shareholders" and will create the number one generics company in Europe and a leader in biosimilars ...
STAT3d
Belgian anti-trust authorities probe Roche for allegedly delaying biosimilars of two cancer meds
The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...
Forbes3d
What Companies Can Do To Address Prescription Drug Market Manipulation
In the American drug industry, a trend has developed among manufacturers and pharmacy benefits managers (PBM) that threatens to upend a productive balance between rewarding manufacturer innovation ...